Abstract
BackgroundAn increased risk of respiratory infections among rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ) has been known through clinical trials and by postmarketing surveillance. So far, little data is...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
